Skip to main content
Premium Trial:

Request an Annual Quote

Owlstone Medical, AstraZeneca Ink Deal for Breath Biomarker Platform

NEW YORK (GenomeWeb) – Owlstone Medical said today it has signed a service agreement with AstraZeneca to study breath-based biomarkers for asthma and COPD.

Under the terms of the agreement, Owlstone will give AstraZeneca access to its Breath Biopsy Services to help the pharmaceutical company identify breath-based biomarkers as well as classification algorithms for the conditions, with the aim of identifying disease phenotypes and the best treatments for those phenotypes.

Financial and other terms of the agreement were not disclosed.

"Through our Breath Biopsy Services we are well positioned to assist the AstraZeneca team to explore how Breath Biopsy can identify novel biomarkers for asthma and COPD and to optimize their application in precision medicine," Owlstone Cofounder and CEO Billy Boyle said in a statement.

A spin-out of the larger Owlstone company, Owlstone Medical uses Field Asymmetric Ion Mobility Spectrometry technology to test patient breath samples for metabolomic biomarkers linked to various disease states. The company is currently developing breath-based tests for the early detection of lung and colorectal cancer.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.